Quick Answer
Beta Bionics, Inc. reported Total Revenue of $100.25 million for fiscal year 2025.
Beta Bionics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $100.25M +53.9% |
$65.12M +442.9% |
$11.99M | — |
| Revenue (ASC 606) | $100.25M +53.9% |
$65.12M +442.9% |
$11.99M | — |
| Net Income | -$73.20M -33.7% |
-$54.76M -24.2% |
-$44.10M | — |
| Diluted EPS | -$1.81 +79.0% |
-$8.60 -3.5% |
-$8.31 | — |
| Total Assets | $328.74M +119.7% |
$149.65M +36.0% |
$110.04M | — |
| Cash and Equivalents | $31.58M +3.8% |
$30.43M +14.6% |
$26.57M | — |
| Stockholders Equity | $287.61M +217.2% |
-$245.36M -20.8% |
-$203.10M -19.4% |
-$170.03M |
| R&D Expense | $34.79M +32.9% |
$26.18M +45.9% |
$17.94M | — |
| Operating Income | -$71.68M -58.4% |
-$45.25M -26.2% |
-$35.85M | — |
| Gross Profit | $55.54M +54.8% |
$35.89M +468.9% |
$6.31M | — |
| Shares Outstanding | 44.36M +565.3% |
6.67M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $27.25M | +63.1% | +17.3% |
| Revenue (ASC 606) | September 30, 2025 | $27.25M | +63.1% | +17.3% |
| Net Income | September 30, 2025 | -$14.21M | -45.9% | +15.8% |
| Diluted EPS | September 30, 2025 | -$0.33 | +77.4% | +15.4% |
| Total Assets | September 30, 2025 | $330.05M | — | +0.0% |
| Cash and Equivalents | September 30, 2025 | $38.48M | +120.2% | +9.7% |
| Stockholders Equity | September 30, 2025 | $294.76M | +228.8% | -2.3% |
| R&D Expense | September 30, 2025 | $8.20M | +59.4% | -7.6% |
| Operating Income | September 30, 2025 | -$17.04M | -55.3% | +14.2% |
| Gross Profit | September 30, 2025 | $15.12M | +69.6% | +20.9% |
| Shares Outstanding | September 30, 2025 | 43.99M | — | +1.2% |
- Beta Bionics, Inc. reported Total Revenue of $100.25 million for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +53.9% in Total Revenue compared to the prior fiscal year.
- Beta Bionics, Inc. reported Revenue (ASC 606) of $100.25 million for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +53.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Beta Bionics, Inc. reported Net Income of -$73.20 million for fiscal year 2025.
- Beta Bionics, Inc. showed a decrease of -33.7% in Net Income compared to the prior fiscal year.
- Beta Bionics, Inc. reported Diluted EPS of $1.81 per share (loss) for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +79.0% in Diluted EPS compared to the prior fiscal year.
- Beta Bionics, Inc. reported Total Assets of $328.74 million for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +119.7% in Total Assets compared to the prior fiscal year.
- Beta Bionics, Inc. reported Cash and Equivalents of $31.58 million for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +3.8% in Cash and Equivalents compared to the prior fiscal year.
- Beta Bionics, Inc. reported Stockholders Equity of $287.61 million for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +217.2% in Stockholders Equity compared to the prior fiscal year.
- Beta Bionics, Inc. reported R&D Expense of $34.79 million for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +32.9% in R&D Expense compared to the prior fiscal year.
- Beta Bionics, Inc. reported Operating Income of -$71.68 million for fiscal year 2025.
- Beta Bionics, Inc. showed a decrease of -58.4% in Operating Income compared to the prior fiscal year.
- Beta Bionics, Inc. reported Gross Profit of $55.54 million for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +54.8% in Gross Profit compared to the prior fiscal year.
- Beta Bionics, Inc. reported Shares Outstanding of 44.36 million shares for fiscal year 2025.
- Beta Bionics, Inc. showed an increase of +565.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: